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Patientswithchronichypergastrinemiaduetochronicatrophicgastritisorgastrinomashaveanincreasedriskofdevelopinggastric
malignancy, and it has been questioned whether also patients with hypergastrinemia caused by long-term use of acid inhibiting
drugs are at risk. Gastric carcinogenesis in humans is aﬀected by numerous factors and progresses slowly over years. When using
animal models with the possibility of intervention, a complex process can be dissected by studying the role of hypergastrinemia in
carcinogenesis within a relatively short period of time. We have reviewed ﬁndings from relevant models where gastric changes in
animal models of long-term hypergastrinemia have been investigated. In all species where long-term hypergastrinemia has been
induced, there is an increased risk of gastric malignancy. There is evidence that hypergastrinemia is a common causative factor in
carcinogenesis in the oxyntic mucosa, while other cofactors may vary in the diﬀerent models.
1.Introduction
Many patients have gastric hypoacidity and secondary
hypergastrinemia due to atrophic gastritis or the use of
proton pump inhibitors, whereas patients with gastrinomas
have hypergastrinemia and increased gastric acidity. There
is evidence that patients with atrophic gastritis have an
increasedriskofbothenterochromaﬃn-like(ECL)cellcarci-
noids as well as gastric adenocarcinomas [1–4]. Patients with
gastrinomasalsohaveanincreasedriskofECLcellcarcinoids
[5–7] and may develop gastric signet ring cell carcinomas
[8]. However, there is no direct evidence that Proton Pump
Inhibitors (PPI) increases the risk of developing gastric
malignancy, but micronodular ECL cell hyperplasia is seen
after 5years of PPI use [9]. Carcinogenesis in humans is
considered a multistep process progressing over years where
various factors may inﬂuence. To study the contribution of
single factors in carcinogenesis, various animal models can
be useful. The major advantage of using animal models is
that carcinogenesis is relatively reliable and often progresses
in months allowing stepwise tumour development to be
studied in detail.
Much of the knowledge we have of regulation of acid
secretion is derived from animal studies and also applies to
growth regulation of the oxyntic mucosa. Gastrin released
fromantralG-cellsisthemainregulatorofacidsecretionand
binds to the CCK-2/gastrin receptor located on the ECL cell
that secretes histamine which in turn stimulates parietal cells
to secretion of hydrochloric acid [10, 11].
Although the evidence of the gastrin-ECL-parietal cell
axis came from studies of the eﬀects of various acid
secretagogues in isolated rat stomachs in the 1980s, more
recent studies conﬁrm these ﬁndings. Fluorescein-labelled
CCK-8 binds to ECL cells but not parietal cells [12], and
gastrin does not stimulate acid secretion in either histidine-
decarboxylase (HDC) deﬁcient [13]o rH 2r e c e p t o rd e ﬁ c i e n t
[14] mice. These ﬁndings are relevant to understand the
trophic and carcinogenic eﬀects of long-term hypergas-
trinemia, where the target cell of gastrin, the ECL cell, is
pivotal.2 Journal of Biomedicine and Biotechnology
In this paper we review ﬁndings from animal studies on
theroleoflong-termhypergastrinemiaingastriccarcinogen-
esis.
2. AnimalModels
2.1. Rats. In 1985 it was published that rats with life-long
acid inhibition by dosing the insurmountable histamine 2-
blockerloxtidinedevelopedECLcellcarcinoids[15].Initially
it was speculated whether the carcinogenic eﬀect was speciﬁc
for this compound, but shortly after it became known
that the proton pump inhibitor omeprazole caused a 15-
fold increase in plasma gastrin [16], tripled the ECL cell
density [17] and resulted in a 20% increase in oxyntic
mucosal thickness after only 10weeks administration. Life-
long administration of omeprazole moreover resulted in
ECL cell carcinoids in rats [18]. As both omeprazole and
loxtidine cause profound gastric hypoacidity and subsequent
hypergastrinemia is was hypothesized that hypergastrinemia
caused ECL cell carcinoid development. Several following
studieswereinsupportofthishypothesis.Infusionofgastrin
was found to stimulate self-replication of ECL cells [19], and
partial corpectomy (also causing hypergastrinemia) resulted
in ECL cell hyperplasia [20] and ECL cell carcinoids [21]i n
the remaining oxyntic mucosa. Long-term administration of
the competitive H2-blocker ranitidine also has the ability to
induce ECL cell carcinoids when given in large enough doses
[22]. Finally, the administration of ciproﬁbrate induces ECL
cell carcinoids [23] in rats without gastric hypoacidity [24],
but causes hypergastrinemia through a direct eﬀect on the
antral G-cell [25]. The induction of ECL cell carcinoids by
ciproﬁbrate clearly demonstrates that it is hypergastrinemia
and not hypoacidity that drives ECL cell carcinogenesis.
2.2. Mice. The consequences of long-term hypergastrinemia
have also been studied in mice by the administration of
antisecretagogues and by the use of various genetically
modiﬁed mice.
Administrationofloxtidinefortwoyearstomiceinduced
carcinoids in the oxyntic mucosa [26], whereas a similar
study with the proton pump inhibitor omeprazole did not
show development of such tumours [18]. However, the mice
were given the same dose omeprazole according to weight
that had previously been given to rats (400μmg/kg/day)
without measuring the eﬀect on gastric acidity and serum
gastrin in mice. Later we have shown that mice are remark-
ablyresistant to protonpump inhibitors withrespectto inhi-
bition of gastric acid secretion and require an extremely high
dose (1750μmg/kg/day subcutaneously) to induce profound
hypoacidity and hypergastrinemia [27]. Consequently, the
omeprazole study [18] was inconclusive and the potential
tumorigenic eﬀect of long-term administration of PPIs in
mice is not settled.
In transgenic INS-GAS mice, it is possible to study
the eﬀect of hypergastrinemia without gastric hypoacidity
[28]. Overexpression of gastrin leads to 4-fold increase in
plasma gastrin and gastric hypersecretion mimicking human
gastrinomas. Young INS-GAS mice have an increased ECL
cell number, but with time, the INS-GAS mice lose both
parietal cells and cells that can be identiﬁed as ECL cells
and some develop adenocarcinomas in the oxyntic mucosa
at the end of their lifespan. Inoculation with Helicobacter
felis further increases plasma gastrin and accelerates car-
cinogenesis considerably [28]. Moreover, the carcinogenesis
is synergistically inhibited by administration of histamine
2 receptor (loxitidine) and gastrin receptor antagonists
(YF476) [29] indicating a role for both mediators in
carcinogenesis. The reason why hypergastrinemic INS-GAS
mice develop tumours with an adenocarcinoma phenotype,
whereasmiceandratsdevelopECLcellcarcinoidsafterlong-
term acid inhibition is not known.
A study comparing diﬀerent mice models suggests that
the carcinogenic eﬀect of Helicobacter infection is mediated
by gastrin. INS-GAS, C57BL/6 and gastrin deﬁcient mice
were inoculated with Helicobacter felis and whereas hyper-
gastrinemic mice developed dysplasia in the oxyntic mucosa,
dysplasia was not found in gastrin-deﬁcient mice [30].
O t h e rm i c em o d e l sa sw e l lc a nb eu s e dt os t u d y
the consequences of hypergastrinemia secondary to gastric
hypoacidity. H+K+ATPase beta subunit-deﬁcient mice are
anacidicandhavea4-to7-foldincreaseinserumgastrinand
show hyperplasia of the oxyntic mucosa [31, 32], whereas
hyperplasia is not seen in H+K+ATPase beta subunit and
gastrin double knockout mice. H+K+ATPase beta subunit-
deﬁcientmicehaveanincreaseinECLcellnumbercompared
to controls, but carcinoma development in the oxyntic
mucosa is rare and expression of neuroendocrine markers
within the carcinoma could not be detected [33]. Similar
changes have been described in H+K+ATPase alpha subunit-
deﬁcient mice [34].
The role of histamine has been studied using HDC-
deﬁcient mice that show gastric hypoacidity and a threefold
increase in plasma gastrin levels [35]. In animals aged 8
to 12weeks there were no diﬀerences in mucosal thickness
suggesting that histamine mediates the trophic eﬀect of gas-
trin, but not via the histamine-2 receptor, since histamine-
2 receptor deﬁcient mice are hypergastrinemic and have
a hypertrophic oxyntic mucosa [14]. Long-term studies
addressing the carcinogenic eﬀects of hypergastrinemia in
the absence of histamine have not been published.
Gastrin-deﬁcient mice do not have basal acid secretion
[36]thusprovidingamodelforstudyingtheeﬀectsofgastric
hypoacidity without hypergastrinemia. These mice develop
a n t r a lt u m o u r sc l a s s i ﬁ e da sa d e n o c a r c i n o m a s[ 37] which are
attributedtobacterialovergrowthandsubsequentformation
of carcinogenic substances [38, 39].
H+K+ATPase and gastrin double knockedout mice are
anacidic without gastrin [31], hence they do not develop a
hypertrophic oxyntic mucosa, demonstrating that gastrin is
responsible for these changes.
Several other genetically modiﬁed mice with gastric
hypoacidity have been made, but studies on long-term
gastric changes have so far not been published. That
is, mice where the gene encoding KCNE2 (a potassium
channel ancillary subunit) is knockedout are hypoacidic and
hypergastrinemic, and these mice have marked hyperplastic
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2.3. Japanese Cotton Rats. Animals from a strain of
Japanese cotton rats develop spontaneous gastric carcinomas
restricted to the oxyntic mucosa with a marked female
preponderance [41]. The animals developing carcinomas
were later found to have gastric hypoacidity, secondary
hypergastrinemia, and pronounced ECL cell hyperplasia
[42]. The oxyntic mucosa in hypergastrinemic cotton rats
has marked hyperplasia of chromogranin A, synaptophysin,
and HDC immunoreactive cells and a proportion of the
tumour cells are chromogranin A, pancreastatin, HDC, and
Sevier-Munger positive [42–45]with similar changes found
in mRNA expression [46, 47]. Between the age of two
and sixmonths, a proportion of female cotton rats develop
gastric hypoacidity by an unknown mechanism, and develop
carcinomas after approximately four months of hypergas-
trinemia. Several studies have demonstrated the importance
of gastrin in tumour development as carcinomas are pre-
vented by injections of a gastrin receptor antagonist (YF476)
[43] ,b yr e m o v a lo fa n t r a lg a s t r i nb ya n t r e c t o m y[ 48]o r
by administration of the somatostatin analogue octreotide
[47]. Male cotton rats that are made hypergastrinemic due
to either administration of loxtidine [49] or by partial
corpectomy [50] also develop carcinomas in the oxyntic
mucosa. The ECL cell ultrastructure and neuroendocrine
immunoreactivity in hypergastrinemic animals have been
observed over time and ECL cells gradually lose charac-
teristics suggesting that ECL cells undergo dediﬀerentiation
during transformation stimulated by hypergastrinemia [45].
Thecottonratmodel demonstratesthattumourswithan
adenocarcinoma phenotype and neuroendocrine character-
istics are induced by gastric hypoacidity and hypergastrine-
mia and probably develop through dediﬀerentiation of ECL
cells.
2.4. Mongolian Gerbils. Studies in both rodents and man
have associated infection with Helicobacter spp. with devel-
opment of gastric carcinomas. In Mongolian Gerbils (“desert
rats”) infection with H. pylori leads to development of
chronicgastritis,pepticulcers,atrophyofthegastricmucosa,
intestinal metaplasia, and ﬁnally gastric carcinomas [3, 51],
thus a disease that parallels what is found in humans.
ThereseemstobeacloserelationshipbetweenHelicobac-
ter infection, elevated gastrin, and development of gastric
carcinomas. Hypergastrinemia is a risk factor for gastric
carcinomas irrespective of Helicobacter infection in both
rodents and man. Infection with H. pylori induces a 5- to
10-fold rise in serum gastrin in Mongolian Gerbils [52]a n d
increases with time [53]. Two phenotypic diﬀerent gastric
tumours can be found in Mongolian Gerbils after long-
term infection with H. pylori; ECL cell carcinoids [3, 53]
and presumably adenocarcinomas [3, 52, 53], suggesting
that these two malignant tumours develop through similar
mechanism.Interestingly,thereisanincreaseinCgApositive
cells up to week 50, which decreases from week 50 to
100 [54], resembling the dediﬀerentiation seen in other
models for studying eﬀects of long-term hypergastrinemia.
It has also been demonstrated that regenerating (reg) gene
expression correlates with hypergastrinemia in H pylori
infected animals [55].
2.5. Mastomys. One of the animal models contributing to
our understanding of gastric carcinoid tumours (neuroen-
docrine tumours, NETs) is the African rodent Mastomys
Natalensis of the family Muridae. Already in the 1950s, it
was discovered that strains of Mastomys had the propensity
to develop multicentric gastric tumours that were ﬁrst
misclassiﬁed as adenocarcinomas [56, 57]. These tumours
were later reclassiﬁed as gastric neuroendocrine tumours
[58, 59], originating from the ECL-cell [60, 61], similar
to the human type I (associated to atrophic gastritis) and
type II (associated with gastrinoma) gastric carcinoids. The
carcinoidsinMastomysarefoundinabout50percentofaged
animals (1-2years) and are located to the oxyntic mucosa.
The pathological changes seen preceding the development
of tumours are summarized in three stages: stage I with
linear hyperplasia of ECL cells, stage II with the development
of ECL-cell nodules restricted to gastric glands, and stage
III with ECL- cell growth below the lamina propria [62].
The direct cause of the ECL cell neoplasia in Mastomys is
uncertain, however closely linked to gastrin and the CCK-
2 receptor activity. The Mastomys CCK2/gastrin receptor
has been transfected to COS-7 cells, and this receptor
has an enhanced basal level of activity compared to the
human receptor [63]. Gastrin is, however, also necessary
in the pathogenesis of the carcinoids as the CCK2/gastrin
receptor antagonist YF476 inhibits both ECL hyperplasia
and gastric tumour development [64]. Loxtidine-induced
hypergastrinemia moreover promotes the development of
carcinoids in Mastomys [61]. The density of ECL cells was
three times that of controls after 24weeks of loxtidine treat-
ment and 1/4 of the animals had gross tumours [61]. ECL
cell hyperplasia and dysplasia, but not tumours, have been
shown to be reversible after cessation of loxtidine treatment,
suggesting that the tumour cells become independent of
hypergastrinemia at some point in the neoplastic process
[65]. The somatostatin-analogue octreotide has inhibitory
eﬀects on both gastrin cells and ECL cells and is found to
prevent loxtidine-induced ECL hyperplasia [66].
2.6. The Norwegian Lundehund. The Norwegian Lunde-
hund, a small Norwegian spitz breed, is a working dog
developed for hunting puﬃns (Fratercula arctica), especially
in the northern part of Norway. The breed was nearly
eradicated during the Second World War because of the
spread of canine distemper virus, and the present population
originates from only ﬁve dogs.
Lundehunds often suﬀer from the “Lundehund syn-
drome”: intermittent diarrhoea, hypoproteinemia, ascites,
subcutaneous oedema, weight loss, and lethargy. Aﬀected
dogs are also known to develop chronic atrophic gastritis
and are predisposed to the development of gastric tumours,
two conditions that are rare in other breeds. The chronic
atrophic gastritis is associated with loss of parietal cells
and linear hyperplasia of ECL cells [67]. These ﬁndings
are consistent with decreased acid secretion and long-term
hypergastrinemia in these dogs.
Gastric carcinomas in dogs usually arise in the pyloric
area. However, in Lundehunds the tumours most often arise4 Journal of Biomedicine and Biotechnology
in the fundic/corpus area, that is, in the oxyntic mucosa [67].
When examining the tumours by means of histochemistry
and immunohistochemistry, the neoplastic cells show neu-
roendocrine and more speciﬁcally ECL cell diﬀerentiation
in half of the tumours [67]. Thus, it is likely that the
carcinomas originate from the ECL cell secondary to the
long-term trophic eﬀect of hypergastrinemia. The neoplastic
processthusparallelsthedevelopmentoftumoursassociated
with pernicious anemia in man [68–70]. About half of
the gastric carcinomas in Lundehund show neuroendocrine
diﬀerentiation. However, during neoplastic progression an
increasing number of mutations lead to dediﬀerentiation of
tumour cells with reduced concentrations or complete loss
of normal cell markers, as shown in Japanese cotton rats [71]
and man [72]. This may explain why it is diﬃcult to detect
neuroendocrine and ECL cell markers in some tumours [70]
and makes it possible that tumours which fail to express such
markers may still be of neuroendocrine origin.
Theeﬀectsoflong-termadministrationofacidinhibitors
has not been studied in the Norwegian Lundehund, but
beagle dogs have been given omeprazole daily for 7years
[73]. There were no changes in the gastric mucosa at termi-
nation including ECL cell numbers, but the dogs receiving
omeprazole had similar fasting and meal-stimulated plasma
gastrin levels compared to controls which means the dogs
had not received an adequate dose of PPI.
3. Discussion
Although the incidence of gastric cancer in western coun-
tries is decreasing, the incidence of adenocarcinomas of
the diﬀuse type is increasing [74], being the subtype of
adenocarcinomas that often develop in patients with hyper-
gastrinemiaandhaveneuroendocrinediﬀerentiation[70,75,
76]. Recently it was also reported that in USA there is a
signiﬁcant increase of noncardia gastric adenocarcinomas in
whites among younger cohorts [77], while the cause of these
new trends is diﬃcult to determine from epidemiological
dataalone.Therelevanceofanimalmodelswherehypotheses
can be tested and new are generated is obvious, as animal
models allow intervention by introducing or eliminating
factors thought to aﬀect carcinogenesis. Hypergastrinemia
is seen in many models of gastric carcinogenesis and seems
to be a common causative factor in otherwise diﬀerent cir-
cumstances. In all species where long-term hypergastrinemia
has been induced, an increased risk of gastric malignancy
is observed, whether hypergastrinemia is accompanied by
either gastric hypoacidity or hyperacidity.
In some animal models hypergastrinemia induces malig-
nancy with either carcinoid or adenocarcinoma phenotype.
However, ﬁndings from Mongolian gerbils and Japanese
cotton rats suggest that these tumours develop by similar
mechanisms and derive from ECL cells, thus resembling
patients with atrophic gastritis who have an increased risk
of developing both types of tumours. More experiments
are needed to identify the mechanisms that determine the
tumour phenotype.
References
[ 1 ]S .R a k i c ,R .A .H i n d e r ,G .A d a n j a ,a n dT .R .D e M e e s t e r ,
“Elevated serum gastrin levels in patients with gastric cancer,”
Journal of Surgical Oncology, vol. 47, no. 2, pp. 79–81, 1991.
[2] H. F. Helander and N. Poorkhalkali, “Parietal cell density
during gastric ulcer healing in the rat,” Scandinavian Journal
of Gastroenterology, vol. 39, no. 1, pp. 20–26, 2004.
[3] T.Watanabe,M.Tada,H.Nagi,S.Sasaki,andM.Nakao,“Heli-
cobacter pylori infection induces gastric cancer in Mongolian
gerbils,” Gastroenterology, vol. 115, no. 3, pp. 642–648, 1998.
[4] I. M. Modlin, M. Kidd, and J. Farhadi, “Bayliss and Starling
and the nascence of endocrinology,” Regulatory Peptides, vol.
93, no. 1-3, pp. 109–123, 2000.
[5] T. D’Adda, S. Candidus, H. Denk, C. Bordi, and H. H¨ oﬂer,
“Gastric neuroendocrine neoplasms: tumour clonality and
malignancy- associatedlargeX-chromosomaldeletions,”Jour-
nal of Pathology, vol. 189, no. 3, pp. 394–401, 1999.
[6] A. K. Sandvik, E. Brenna, A. Sundan, J. J. Holst, and H. L.
Waldum, “Bombesin inhibits histamine release from the rat
oxyntic mucosa by a somatostatin-dependent mechanism,”
Scandinavian Journal of Gastroenterology,v o l .3 2 ,n o .5 ,p p .
427–432, 1997.
[7] T. D’Adda, A. Bertele, F. P. Pilato, and C. Bordi, “Quantitative
electron microscopy of endocrine cells in oxyntic mucosa of
normal human stomach,” Cell and Tissue Research, vol. 255,
no. 1, pp. 41–48, 1989.
[8] M. Schott, C. Sagert, H. S. Willenberg et al., “Carcinogenic
hypergastrinemia: signet-ring cell carcinoma in a patient with
multiple endocrine neoplasia type 1 with zollinger-ellison’s
syndrome,” Journal of Clinical Endocrinology and Metabolism,
vol. 92, no. 9, pp. 3378–3382, 2007.
[9] R. Fiocca, L. Mastracci, S. E. Attwood et al., “Exocrine and
endocrine gastric mucosal changes under medical or surgical
antireﬂux therapy: results of a 5-year follow-up in the LOTUS
trial,” Gastroenterology, vol. 138, article W1092, 2010.
[10] H. L. Waldum, A. K. Sandvik, E. Brenna, and H. Petersen,
“Gastrin-histamine sequence in the regulation of gastric acid
secretion,” Gut, vol. 32, no. 6, pp. 698–701, 1991.
[11] N. P. Shankley, N. J. Welsh, and J. W. Black, “Histamine
dependence of pentagastrin-stimulated gastric acid secretion
in rats,” Yale Journal of Biology and Medicine, vol. 65, no. 6, pp.
613–619, 1992.
[12] I. Bakke, G. Qvigstad, A. K. Sandvik, and H. L. Waldum, “The
CCK-2 receptor is located on the ECL cell, but not on the
parietalcell,”ScandinavianJournalofGastroenterology,vol.36,
no. 11, pp. 1128–1133, 2001.
[13] F.SundlerandR.Haakanson,“Gastricendocrinecelltypingat
the light microscopical level,” in The Stomach as an Endocrine
Organ, F. Sundler and R. Haakanson, Eds., pp. 9–26, Elsevier
Science, Amsterdam, The Netherlands, 1991.
[14] M. Asahara, S. Mushiake, S. Shimada et al., “Reg gene
expression is increased in rat gastric enterochromaﬃn-like
cells following water immersion stress,” Gastroenterology, vol.
111, no. 1, pp. 45–55, 1996.
[15] D. Poynter, C. R. Pick, R. A. Harcourt et al., “Association
of long lasting unsurmountable histamine H2 blockade and
gastric carcinoid tumours in the rat,” Gut, vol. 26, no. 12, pp.
1284–1295, 1985.
[16] H. Larsson, E. Carlsson, H. Mattsson et al., “Plasma gastrin
and gastric enterochromaﬃnlike cell activation and prolifer-
ation. Studies with omeprazole and ranitidine in intact and
antrectomized rats,” Gastroenterology, vol. 90, no. 2, pp. 391–
399, 1986.Journal of Biomedicine and Biotechnology 5
[17] F. Sundler, R. Hakanson, E. Carlsson, H. Larsson, and H.
Mattsson, “Hypergastrinemia after blockade of acid secretion
intherat:trophiceﬀects,”Digestion,vol. 35,supplement1,pp.
56–69, 1986.
[18] N. Havu, “Enterochromaﬃn-like cell carcinoids of gastric
mucosa in rats after life-long inhibition of gastric secretion,”
Digestion, vol. 35, no. 1, pp. 42–55, 1986.
[19] B. Ryberg, Y. Tielemans, J. Axelson et al., “Gastrin stimulates
the self-replication rate of enterochromaﬃnlike cells in the rat
stomach: eﬀects of omeprazole, ranitidine, and gastrin-17 in
intact and antrectomized rats,” Gastroenterology, vol. 99, no.
4, pp. 935–942, 1990.
[20] B. Ryberg, E. Carlsson, R. Hakanson, L. Lundell, H. Mattsson,
and F. Sundler, “Eﬀects of partial resection of acid-secreting
mucosa on plasma gastrin and enterochromaﬃn-like cells in
the rat stomach,” Digestion, vol. 45, no. 2, pp. 102–108, 1990.
[21] H. Mattsson, N. Havu, J. Brautigam, K. Carlsson, L. Lundell,
and E. Carlsson, “Partial gastric corpectomy results in hyper-
gastrinemia and development of gastric enterochromaﬃnlike-
cell carcinoids in the rat,” Gastroenterology, vol. 100, no. 2, pp.
311–319, 1991.
[22] N. Havu, H. Mattsson, L. Ekman, and E. Carlsson,
“Enterochromaﬃn-like cell carcinoids in the rat gastric
mucosa following long-term administration of raniditine,”
Digestion, vol. 45, no. 4, pp. 189–195, 1990.
[ 2 3 ]A .J .S p e n c e r ,T .A .B a r b o l t ,D .C .H e n r y ,C .T .E a s o n ,R .
J. Sauerschell, and F. W. Bonner, “Gastric morphological
changes including carcinoid tumors in animals treated with a
potent hypolipidemic agent, ciproﬁbrate,” Toxicologic Pathol-
ogy, vol. 17, no. 1 I, pp. 7–15, 1989.
[24] T. C. Martinsen, N. Nesjan, K. Rønning, A. K. Sandvik,
and H. L. Waldum, “The peroxisome-proliferator ciproﬁbrate
induces hypergastrinemia without raising gastric pH,” Car-
cinogenesis, vol. 17, no. 10, pp. 2153–2155, 1996.
[25] T. C. Martinsen, I. Bakke, D. Chen et al., “Ciproﬁbrate stimu-
lates the gastrin-producing cell by acting luminally on antral
PPAR-α,” American Journal of Physiology—Gastrointestinal
and Liver Physiology, vol. 289, no. 6, pp. G1052–G1060, 2005.
[ 2 6 ]D .P o y n t e r ,S .A .M .S e l w a y ,S .A .P a p w o r t h ,a n dS .R .R i c h e s ,
“Changes in the gastric mucosa of the mouse associated with
long lasting unsurmountable histamine H2 blockade,” Gut,
vol. 27, no. 11, pp. 1338–1346, 1986.
[27] H. L. Waldum, E. Brenna, and T. Chr. Martinsen, “Safety
of proton pump inhibitors,” Alimentary Pharmacology and
Therapeutics, vol. 14, no. 11, pp. 1537–1538, 2000.
[28] T. C. Wang, C. A. Dangler, D. Chen et al., “Synergistic interac-
tion between hypergastrinemia and Helicobacter infection in
a mouse model of gastric cancer,” Gastroenterology, vol. 118,
no. 1, pp. 36–47, 2000.
[29] S. Takaishi, G. Cui, D. M. Frederick et al., “Synergistic
inhibitoryeﬀectsofgastrinandhistaminereceptorantagonists
onHelicobacter-inducedgastriccancer,”Gastroenterology,vol.
128, no. 7, pp. 1965–1983, 2005.
[30] S. Takaishi, S. Tu, Z. A. Dubeykovskaya et al., “Gastrin
is an essential cofactor for Helicobacter-associated gastric
corpus carcinogenesis in C57BL/6 mice,” American Journal of
Pathology, vol. 175, no. 1, pp. 365–375, 2009.
[31] T. V. Franic, L. M. Judd, D. Robinson et al., “Regulation of
gastric epithelial cell development revealed in H+/K+-ATPase
β-subunit- and gastrin-deﬁcient mice,” American Journal of
Physiology—GastrointestinalandLiverPhysiology,vol.281,no.
6, pp. G1502–G1511, 2001.
[32] K. L. Scarﬀ, L. M. Judd, B.-H. Toh, P. A. Gleeson, and I. R. van
Driel, “Gastric H+,K+-adenosine triphosphatase β subunit is
required for normal function, development, and membrane
structure of mouse parietal cells,” Gastroenterology, vol. 117,
no. 3, pp. 605–618, 1999.
[33] K. E. Bakkelund, H. L. Waldum, I. S. Nordrum, O. Hauso,
and R. Fossmark, “Long-term gastric changes in achlorhydric
H+/K+-ATPase beta subunit deﬁcient mice,” Scandinavian
JournalofGastroenterology,vol.45,no.9,pp.1042–1047,2010.
[34] L. M. Judd, A. Andringa, C. A. Rubio, Z. Spicer, G. E.
Shull, and M. L. Miller, “Gastric achlorhydria in H/K-
ATPase-deﬁcient (Atp4a(-/-)) mice causes severe hyperplasia,
mucocystic metaplasia and upregulation of growth factors,”
Journal of Gastroenterology and Hepatology, vol. 20, no. 8, pp.
1266–1278, 2005.
[35] S. Tanaka, K. Hamada, N. Yamada et al., “Gastric acid
secretion in L-histidine decarboxylase-deﬁcient mice,” Gas-
troenterology, vol. 122, no. 1, pp. 145–155, 2002.
[36] L. Friis-Hansen, F. Sundler, Y. Li et al., “Impaired gastric
acid secretion in gastrin-deﬁcient mice,” American Journal of
Physiology—GastrointestinalandLiverPhysiology,vol.274,no.
3, pp. G561–G568, 1998.
[37] L. Friis-Hansen, K. Rieneck, H. Nilsson, T. Wadstr¨ om, and
J. F. Rehfeld, “Gastric inﬂammation, metaplasia, and tumor
development in gastrin-deﬁcient mice,” Gastroenterology, vol.
131, no. 1, pp. 246–258, 2006.
[38] L. Friis-Hansen, “Achlorhydria is associated with gastric
microbial overgrowth and development of cancer: lessons
learned from the gastrin knockout mouse,” Scandinavian
Journal of Clinical and Laboratory Investigation,v o l .6 6 ,n o .7 ,
pp. 607–622, 2006.
[39] L. Friis-Hansen, “Lessons from the gastrin knockout mice,”
Regulatory Peptides, vol. 139, no. 1–3, pp. 5–22, 2007.
[40] T. K. Roepke, A. Anantharam, P. Kirchhoﬀ et al., “The KCNE2
potassiumchannelancillarysubunitisessentialforgastricacid
secretion,” Journal of Biological Chemistry, vol. 281, no. 33, pp.
23740–23747, 2006.
[41] S. Kawase and H. Ishikura, “Female-predominant occurrence
of spontaneous gastric adenocarcinoma in cotton rats,” Labo-
ratory Animal Science, vol. 45, no. 3, pp. 244–248, 1995.
[42] H. L. Waldum, H. Røryik, S. Falkmer, and S. Kawase, “Neu-
roendocrine (ECL cell) diﬀerentiation of spontaneous gastric
carcinomas of cotton rats (Sigmodon hispidus),” Laboratory
Animal Science, vol. 49, no. 3, pp. 241–247, 1999.
[43] T. C. Martinsen, S. Kawase, R. H˚ akanson et al., “Spontaneous
ECL cell carcinomas in cotton rats: natural course and
prevention by a gastrin receptor antagonist,” Carcinogenesis,
vol. 24, no. 12, pp. 1887–1896, 2003.
[44] R. Fossmark, T. C. Martinsen, K. E. Bakkelund, S. Kawase,
S. H. Torp, and H. L. Waldum, “Hypergastrinaemia
induced by partial corpectomy results in development of
enterochromaﬃn-like cell carcinoma in male Japanese cotton
rats,” Scandinavian Journal of Gastroenterology, vol. 39, no. 10,
pp. 919–926, 2004.
[45] R.Fossmark,C.-M.Zhao,T.C.Martinsen,S.Kawase,D.Chen,
and H. L. Waldum, “Dediﬀerentiation of enterochromaﬃn-
like cells in gastric cancer of hypergastrinemic cotton rats,”
APMIS, vol. 113, no. 6, pp. 436–449, 2005.
[46] G. Cui, G. Qvigstad, S. Falkmer, A. K. Sandvik, S.
Kawase, and H. L. Waldum, “Spontaneous ECLomas in
cotton rats (Sigmodon hispidus): tumours occurring in
hypoacidic/hypergastrinaemic animals with normal parietal
cells,” Carcinogenesis, vol. 21, no. 1, pp. 23–27, 2000.
[47] R. Fossmark, T. C. Martinsen, S. H. Torp, S. Kawase, A. K.
Sandvik, and H. L. Waldum, “Spontaneous enterochromaﬃn-
like cell carcinomas in cotton rats (Sigmodon hispidus) are6 Journal of Biomedicine and Biotechnology
prevented by a somatostatin analogue,” Endocrine-Related
Cancer, vol. 11, no. 1, pp. 149–160, 2004.
[48] K.Bakkelund,R.Fossmark,I.S.Nordrum,andH.L.Waldum,
“Eﬀect of antrectomy in hypergastrinaemic female Japanese
cotton rats,” Scandinavian Journal of Gastroenterology, vol. 44,
no. 1, pp. 32–39, 2009.
[49] W.Blumenfeld,D.K.Chandhoke,P.Sagerman,andG.K.Turi,
“Neuroendocrine diﬀerentiation in gastric adenocarcinomas:
an immunohistochemical study,” Archives of Pathology and
Laboratory Medicine, vol. 120, no. 5, pp. 478–481, 1996.
[50] G. P. Lawton, L. Tang, M. Kidd, R. Chinery, K. Miu, and
I. M. Modlin, “Regulation of mastomys ECL cell function
by transforming growth factor alpha,” Journal of Surgical
Research, vol. 60, no. 2, pp. 293–302, 1996.
[51] S. Honda, T. Fujioka, M. Tokieda, R. Satoh, A. Nishizono,
and M. Nasu, “Development of Helicobacter pylori-induced
gastric carcinoma in Mongolian gerbils,” Cancer Research, vol.
58, no. 19, pp. 4255–4259, 1998.
[52] F. Hirayama, S. Takagi, E. Iwao, Y. Yokoyama, K. Haga, and
S. Hanada, “Development of poorly diﬀerentiated adenocar-
cinoma and carcinoid due to long-term Helicobacter pylori
colonization in Mongolian gerbils,” Journal of Gastroenterol-
ogy, vol. 34, no. 4, pp. 450–454, 1999.
[53] J. Kagawa, S. Honda, M. Kodama, R. Sato, K. Murakami, and
T. Fujioka, “Enterocromaﬃn-like cell tumor induced by Heli-
cobacter pylori infection in Mongolian gerbils,” Helicobacter,
vol. 7, no. 6, pp. 390–397, 2002.
[54] Y. Takenaka, T. Tsukamoto, T. Mizoshita et al., “Helicobacter
pylori infection stimulates intestinalization of endocrine cells
in glandular stomach of Mongolian gerbils,” Cancer Science,
vol. 97, no. 10, pp. 1015–1022, 2006.
[55] H. Fukui, F. Franceschi, R. L. Penland et al., “Eﬀects of
helicobacter pylori infection on the link between regenerating
gene expression and serum gastrin levels in Mongolian
gerbils,” Laboratory Investigation, vol. 83, no. 12, pp. 1777–
1786, 2003.
[56] A. G. Oettele, “Spontaneous carcinoma of the glandular stom-
ach in a laboratory stock of Rattus (Mastomys) natalensis,”
South African Journal of Medical Sciences, vol. 20, article 36,
1955.
[57] A. G. Oettele, “Spontaneous carcinoma of the glandular
stomach in Rattus (mastomys) natalensis, an African rodent,”
British Journal of Cancer, vol. 11, pp. 415–433, 1957.
[58] J. Soga, H. Kanahara, and K. Hiraide, “Some characteristic
featuresofspontaneousargyrophilcellcarcinoidsinglandular
stomach of Praomys (Mastomys) natalensis,” GANN Mono-
graph, vol. 8, pp. 15–38, 1969.
[59] K. C. Snell and H. L. Stewart, “Malignant argyrophilic gastric
carcinoids of Praomys (Mastomys) natalensis,” Science, vol.
163, no. 866, p. 470, 1969.
[60] S. Hosoda, W. Nakamura, K. C. Snell, and H. L. Stewart,
“Histamine production by transplantable argyrophilic gastric
carcinoid of praomys (Mastomys) natalensis,” Science, vol.
170, no. 3956, pp. 454–455, 1970.
[61] O. Nilsson, B. Wangberg, L. Johansson et al., “Rapid induction
of enterochromaﬃnlike cell tumors by histamine2- receptor
blockade,” American Journal of Pathology, vol. 142, no. 4, pp.
1173–1185, 1993.
[62] J. Soga, T. Kohro, K. Tazawa, H. Kanahara, and M. Sano,
“Argyrophil cell microneoplasia in the Mastomys’ stomach.
An observation on early carcinoid formation,” Journal of the
National Cancer Institute, vol. 55, no. 4, pp. 1001–1006, 1975.
[63] K. Schaﬀer, E. W. McBride, M. Beinborn, and A. S. Kopin,
“Interspecies polymorphisms confer constitutive activity to
the Mastomys cholecystokinin-B/gastrin receptor,” Journal of
Biological Chemistry, vol. 273, no. 44, pp. 28779–28784, 1998.
[64] M.Kidd,Z.L.Siddique, I.Drozdovetal.,“The CCK2receptor
antagonist, YF476, inhibits Mastomys ECL cell hyperplasia
and gastric carcinoid tumor development,” Regulatory Pep-
tides, vol. 162, no. 1–3, pp. 52–60, 2010.
[65] B. W¨ angberg, O. Nilsson, E. Theodorsson, I. M. Modlin, A.
Dahlstr¨ om, and H. Ahlman, “Are enterochromaﬃnlike cell
tumours reversible? An experimental study on gastric carci-
noidsinducedinMastomysbyhistamine2-receptorblockade,”
Regulatory Peptides, vol. 56, no. 1, pp. 19–33, 1995.
[66] I. M. Modlin, R. Kumar, A. Nangia, C. J. Soroka, D. Pasikhov,
and J. R. Goldenring, “Gastrin-dependent inhibitory eﬀects of
octreotide on the genesis of gastric ECLomas,” Surgery, vol.
112, no. 6, pp. 1048–1058, 1992.
[67] G. Qvigstad, ∅. Kolbjørnsen, E. Skancke, and H. L. Waldum,
“Gastric neuroendocrine carcinoma associated with atrophic
gastritis in the Norwegian Lundehund,” Journal of Compara-
tive Pathology, vol. 139, no. 4, pp. 194–201, 2008.
[68] L. Elsborg and J. Mosbech, “Pernicious anemia as a risk factor
in gastric cancer,” Acta Medica Scandinavica, vol. 206, no. 4,
pp. 315–318, 1979.
[69] K. Borch, H. Renvall, and G. Liedberg, “Gastric endocrine
cell hyperplasia and carcinoid tumors in pernicious anemia,”
Gastroenterology, vol. 88, no. 3, pp. 638–648, 1985.
[70] G. Qvigstad, T. Qvigstad, B. Westre, A. K. Sandvik, E. Brenna,
and H. L. Waldum, “Neuroendocrine diﬀerentiation in gastric
adenocarcinomas associated with severe hypergastrinemia
and/or pernicious anemia,” APMIS, vol. 110, no. 2, pp. 132–
139, 2002.
[71] R.Fossmark,C.-M.Zhao,T.C.Martinsen,S.Kawase,D.Chen,
and H. L. Waldum, “Dediﬀerentiation of enterochromaﬃn-
like cells in gastric cancer of hypergastrinemic cotton rats,”
APMIS, vol. 113, no. 6, pp. 436–449, 2005.
[72] G. Qvigstad, S. Falkmer, B. Westre, and H. L. Waldum,
“Clinical and histopathological tumour progression in ECL
cell carcinoids (’ECLomas’),” APMIS, vol. 107, no. 12, pp.
1085–1092, 1999.
[73] C.Safholm,N.Havu,H.Forssell,G.Sundell,andH.Mattsson,
“Eﬀect of 7 years’ daily oral administration of omeprazole to
beagle dogs,” Digestion, vol. 55, no. 3, pp. 139–147, 1994.
[74] D. E. Henson, C. Dittus, M. Younes, H. Nguyen, and J.
Albores-Saavedra, “Diﬀerential trends in the intestinal diﬀuse
types of gastric carcinoma in the United States, 1973–2000:
increase in the signet ring cell type,” Archives of Pathology and
Laboratory Medicine, vol. 128, no. 7, pp. 765–770, 2004.
[75] G. Qvigstad, A. K. Sandvik, E. Brenna, S. Aase, and H. L.
Waldum, “Detection of chromogranin A in human gastric
adenocarcinomas using a sensitive immunohistochemical
technique,” Histochemical Journal, vol. 32, no. 9, pp. 551–556,
2000.
[76] K. Bakkelund, R. Fossmark, I. Nordrum, and H. Waldum,
“Signet ring cells in gastric carcinomas are derived from
neuroendocrine cells,” Journal of Histochemistry and Cyto-
chemistry, vol. 54, no. 6, pp. 615–621, 2006.
[ 7 7 ]W .F .A n d e r s o n ,M .C .C a m a r g o ,J .F .F r a u m e n iJ r . ,P .C o r r e a ,
P. S. Rosenberg, and C. S. Rabkin, “Age-speciﬁc trends in
incidence of noncardia gastric cancer in US adults,” Journal of
the American Medical Association, vol. 303, no. 17, pp. 1723–
1728, 2010.